Ligand Pharmaceuticals | LGND - Gross Profit On Sales


Ligand Pharmaceuticals reported $155.28M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Agenus USD 34.2M 4.61M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Baxter International USD 577M 373M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Enviri Corporation USD 83.01M 37.46M Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
Intrexon USD -297K 167K Jun/2024
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Merck USD 13.42B 431M Sep/2025
Pacira USD 142.25M 11.34M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Veracyte USD 101.97M 10.69M Dec/2025